問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Principal Investigator

林家齊

List

270Cases

2023-08-15 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2022-10-28 - 2025-11-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2022-11-01 - 2026-01-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Not yet recruiting1Sites

2016-10-20 - 2024-11-22

Phase I

Completed
A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    FAZ053 & PDR001

Participate Sites
1Sites

Terminated1Sites

2021-04-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2019-10-03 - 2025-05-05

Phase I

Completed
A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    DKY709

Participate Sites
1Sites

Recruiting1Sites

2020-03-02 - 2023-09-15

Phase I

Completed
A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    KAZ954, Spartalizumab, NZV930 & NIR178

Participate Sites
1Sites

Not yet recruiting1Sites

2019-08-01 - 2030-04-30

Phase I

Active
An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments

  • Condition/Disease

    Advanced Solid Tumors

  • Test Drug

    Spartalizumab (PDR001)

Participate Sites
1Sites

Recruiting1Sites

2019-03-01 - 2025-12-31

Phase I

Completed
An Open-label, Multi-center, Phase I, Dose Finding Study of Oral TNO155 in Adult Patients With Advanced Solid Tumors

  • Condition/Disease

    Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

  • Test Drug

    TNO155

Participate Sites
1Sites

Recruiting1Sites

2010-11-01 - 2012-12-31

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 12 13 14 15 16 27
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB